About Chembio
Chembio is a company based in Medford (United States) founded in 1986 was acquired by Biosynex in January 2023. The company has 213 employees as of December 31, 2022. Chembio has completed 1 acquisition, including Orangelife Comercio E Industria. Chembio offers products and services including DPP HIV-Syphilis Assay, DPP HIV 1/2 Assay, SURE CHECK HIV Self-Test, DPP Zika IgM/IgG System, and Advin COVID-19 Antigen Test. Chembio operates in a competitive market with competitors including Souzhou Ribo Life Science, PathoQuest, Quantalife, Senzo and Hememics Biotechnologies, among others.
- Headquarter Medford, United States
- Employees 213 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Chembio Diagnostics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Chembio
Chembio offers a comprehensive portfolio of products and services, including DPP HIV-Syphilis Assay, DPP HIV 1/2 Assay, SURE CHECK HIV Self-Test, DPP Zika IgM/IgG System, and Advin COVID-19 Antigen Test.
Rapid test for detecting HIV and syphilis in blood samples.
Assay for identifying HIV types 1 and 2 quickly and accurately.
Home-based test kit for HIV detection with easy user instructions.
System for detecting Zika virus antibodies in clinical settings.
Antigen test for rapid COVID-19 detection at home or point-of-care.
People of Chembio
Unlock access to complete
Funding Insights of Chembio
- Total Funding Total Funding
- Total Rounds 6
- Last Round Debt – Conventional — $20.0M
-
First Round
First Round
(01 Jun 2007)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2019 | Amount | Debt – Conventional - Chembio | Valuation |
investors |
|
| Feb, 2011 | Amount | Grant - Chembio | Valuation |
investors |
|
| Jun, 2009 | Amount | Grant - Chembio | Valuation |
investors |
Investors in Chembio
Chembio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Biosynex and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Professional rapid diagnostic tests for diseases are manufactured by Biosynex.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Chembio
Chembio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Orangelife Comercio E Industria.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Diagnostic test kits are manufactured for healthcare applications.
|
2011 |
Financial Statements - Chembio
Chembio Comparisons
Competitors of Chembio
Chembio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Souzhou Ribo Life Science, PathoQuest, Quantalife, Senzo and Hememics Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Nucleic acid drugs are developed via RNA interference technology.
|
|
| domain | founded_year | HQ Location |
Next-generation sequencing is provided for microbiology testing applications.
|
|
| domain | founded_year | HQ Location |
Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.
|
|
| domain | founded_year | HQ Location |
Point-of-care diagnostic devices for infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Biopreservation platform for mammalian cells and biologics is developed.
|
Frequently Asked Questions about Chembio
Chembio was founded in 1986 and raised its 1st funding round 21 years after it was founded.
Chembio is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.
Richard Eberly is the current CEO of Chembio.
As of Dec 31, 2022, the latest employee count at Chembio is 213.
Annual revenue of Chembio is $49.52M as on Dec 31, 2022.
Chembio Diagnostics, Inc. was established in 1986 in Medford, United States, within the medical diagnostics sector. Rapid tests for infectious diseases, including two FDA PMA-approved, CLIA-waived HIV assays, are produced using the patented Dual Path Platform technology. In the U.S., these HIV tests are distributed by Alere, Inc. Internationally, the HIV STAT-PAK line is supplied to government and donor-funded programs through direct sales and distributors.
Chembio's top competitors include Souzhou Ribo Life Science, Quantalife and Senzo.
Chembio offers DPP HIV-Syphilis Assay, DPP HIV 1/2 Assay, SURE CHECK HIV Self-Test, DPP Zika IgM/IgG System, and Advin COVID-19 Antigen Test.
Chembio has made 1 acquisition, including Orangelife Comercio E Industria.
Chembio has 3 investors. Key investors include HHS, Biosynex, and Perceptive Advisors.